Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz

Blood (2024) 144 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2024-205697

Published: 2024

Journal Articles

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Michael Wang, Patrick Connor Johnson, Salim Yazji, Yisrael Katz, Angela Pietrofeso, James Robinson, Matthew Mei, Matthew J. Frigault, James B. Breitmeyer, Caron A. Jacobson

Blood (2024) 144 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2024-200998

Published: 2024

Journal Articles

Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Anna Barata, Richard Newcomb, Patrick Connor Johnson, Ella Caruso, Porsha Lark, Emelia J. Farnam, Thomas W. LeBlanc, Stephanie J. Lee, Areej El-Jawahri

Blood (2024) 144 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2024-202065

Published: 2024

Journal Articles

Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas

Patrick Connor Johnson, Richard Newcomb, Jeremy S. Abramson, Ann S. LaCasce, Julia Rice, Daniel Yang, Bridget Coffey, Sruthi K. Venkatachalam, Netana H. Markovitz, Emilia Kaslow-Zieve, Oreofe O. Odejide, Areej El-Jawahri

Blood (2024) 144 (Supplement 1): 400.

https://doi.org/10.1182/blood-2024-205279

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Elisa Ten Hacken, Johan Gustafsson, Chiara Tomasoni, Gabriela Brunsting Hoffmann, Kayla Cruz, Wesley S Lu, Shuqiang Li, Nicholas Haradhvala, Connor Johnson, Stephanie Deng, Xia Bu, Donna S. Neuberg, Othman Al-Sawaf, Barbara F. Eichhorst, Clare Sun, Erin M. Parry, Gordon J. Freeman, Gad Getz, Catherine J. Wu

Blood (2024) 144 (Supplement 1): 761.

https://doi.org/10.1182/blood-2024-201006

Published: 2024

Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation

Blood blood.2024025563.

https://doi.org/10.1182/blood.2024025563

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

Netana Markovitz, Oreofe O. Odejide, Areej El-Jawahri, Patrick Connor Johnson

Blood (2023) 142 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2023-187708

Published: 2023

Journal Articles

Pilot Randomized Controlled Trial of an Educational Video for Chimeric Antigen Receptor (CAR)-T Cell Therapy Recipients

Patrick Connor Johnson, Tejaswini Dhawale, Richard Newcomb, Anna Barata, Kyle Karpinski, Mitchell Lavoie, Dagny Vaughn, Kathleen Hennessey, David Scheider, Hermioni L Amonoo, Angelo Volandes, Areej El-Jawahri

Blood (2023) 142 (Supplement 1): 255.

https://doi.org/10.1182/blood-2023-172776

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Longitudinal Patient-Reported Outcomes and Clinical Outcomes By VES-13 and Comprehensive Geriatric Assessment in Older Adults with Aggressive Non-Hodgkin Lymphomas

Patrick Connor Johnson, Netana Markovitz, Richard Newcomb, Daniel Yang, Julia Rice, Bridget Coffey, Oreofe O. Odejide, Areej El-Jawahri

Blood (2023) 142 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2023-187346

Published: 2023

Journal Articles

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 738.

https://doi.org/10.1182/blood-2023-180069

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2023-184345

Published: 2023

Journal Articles

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Philipp Karschnia, Kevin C. Miller, Andrew J. Yee, Kai Rejeski, P. Connor Johnson, Noopur Raje, Matthew J. Frigault, Jorg Dietrich

Blood (2023) 142 (14): 1243–1248.

https://doi.org/10.1182/blood.2023020571

Published: 2023

Journal Articles

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Tejaswini Dhawale, P. Connor Johnson, Mahmoud R. Gaballa, Ashley Nelson, Mitchell W. Lavoie, Matthew Frigault, Kofi Boateng, Claire Greydanus, Areej El-Jawahri

Blood (2022) 140 (Supplement 1): 10989–10990.

https://doi.org/10.1182/blood-2022-162494

Published: 2022

Journal Articles

Characteristics of Lymphoma Patients Experiencing Unplanned Readmissions at a Large Academic Medical Center

Uvette Lou, Matthew M Lei, Mark Sorial, Daniel Lage, Kenechukwu Aniagboso, Emily Buttermore, Margaret Soriano, Ryan D. Nipp, Patrick Connor Johnson

Blood (2022) 140 (Supplement 1): 13088–13089.

https://doi.org/10.1182/blood-2022-168129

Published: 2022

Journal Articles

Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation

Netana H. Markovitz, Areej El-Jawahri, Ciara Dale, Patrick Connor Johnson, Kofi Boateng, Daniel Yang, Hermioni L. Amonoo

Blood (2022) 140 (Supplement 1): 8137.

https://doi.org/10.1182/blood-2022-167964

Published: 2022

Journal Articles

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Patrick Connor Johnson, Tejaswini Dhawale, Mitchell W. Lavoie, Kyle Karpinski, Netana H. Markovitz, Kathleen Hennessey, Matthew Frigault, Areej El-Jawahri

Blood (2022) 140 (Supplement 1): 5232–5233.

https://doi.org/10.1182/blood-2022-163194

Published: 2022

Journal Articles

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 2253–2255.

https://doi.org/10.1182/blood-2022-162583

Published: 2022

Journal Articles

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Blood (2022) 140 (Supplement 1): 1530–1533.

https://doi.org/10.1182/blood-2022-160335

Published: 2022

NARROW

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

Pilot Randomized Controlled Trial of an Educational Video for Chimeric Antigen Receptor (CAR)-T Cell Therapy Recipients

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Longitudinal Patient-Reported Outcomes and Clinical Outcomes By VES-13 and Comprehensive Geriatric Assessment in Older Adults with Aggressive Non-Hodgkin Lymphomas

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Characteristics of Lymphoma Patients Experiencing Unplanned Readmissions at a Large Academic Medical Center

Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only